Institutional Fund
Adar1 Capital Management, LLC
Austin, TXCIK 19402726 filings on record
Portfolio Value
$1.65B
Q1 2026
Holdings
291
Reported positions
New Buys
72
Opened this quarter
QoQ Change
+23.5%
from $1.34B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Abivax SA9.4%
- Protagonist Therapeutics Inc6.3%
- Roivant Sciences Ltd5.5%
- Immunovant Inc4.0%
- Spdr S&P 500 ETF Tr3.0%
- Terns Pharmaceuticals Inc2.9%
- Other68.8%
Portfolio Holdings
291 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Abivax SA | 1.39M | $155.22M | 9.4% | +76.7K | Added |
| 2 | Protagonist Therapeutics Inc | 994.1K | $104.78M | 6.3% | −55.0K | Reduced |
| 3 | Roivant Sciences Ltd | 3.29M | $91.02M | 5.5% | −143.1K | Reduced |
| 4 | Immunovant Inc | 2.68M | $66.55M | 4.0% | +198.0K | Added |
| 5 | Spdr S&P 500 ETF Tr | 75.9K | $49.39M | 3.0% | +21.3K | Added |
| 6 | Terns Pharmaceuticals Inc | 914.7K | $48.22M | 2.9% | +373.1K | Added |
| 7 | Cytokinetics Inc | 632.6K | $41.69M | 2.5% | +92.4K | Added |
| 8 | Crinetics Pharmaceuticals In | 1.14M | $41.38M | 2.5% | +830.0K | Added |
| 9 | Ea Series Trust | 337.1K | $39.20M | 2.4% | 0 | Held |
| 10 | Denali Therapeutics Inc | 1.87M | $35.93M | 2.2% | +1.82M | Added |
281 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio